Moleculin Biotech, Inc. Announces Immediate Exercise of Warrants

HOUSTON, Feb. 13, 2025 /PRNewswire/ —

Moleculin Biotech, Inc. (Nasdaq: MBRX), a late-stage pharmaceutical company focused on developing drugs for hard-to-treat tumors and viruses, has recently made a significant announcement. The company has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to 5,828,570 shares of common stock.

These warrants were originally issued in December 2023 and August 2024, and the exercise price has been reduced to $1.00 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-1.

Impact on Individuals

The immediate exercise of warrants by Moleculin Biotech, Inc. could have a direct impact on individuals who hold these warrants. By exercising the warrants at a reduced price, shareholders may have the opportunity to increase their stake in the company at a more affordable rate.

Global Impact

From a broader perspective, the immediate exercise of warrants by Moleculin Biotech, Inc. could have far-reaching effects on the pharmaceutical industry and the world at large. By expanding their portfolio of drug candidates targeting hard-to-treat tumors and viruses, the company may be paving the way for innovative treatments that could benefit patients worldwide.

Conclusion

In conclusion, Moleculin Biotech, Inc.’s announcement regarding the immediate exercise of warrants represents a significant development in the pharmaceutical industry. With a focus on developing treatments for challenging medical conditions, the company is positioned to make a meaningful impact on individuals and the world as a whole.